A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma.

Trial Profile

A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Bexarotene (Primary) ; Pralatrexate (Primary) ; Folic acid; Vitamin B12 analogues
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Adverse reactions
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 20 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top